Alligator Bioscience Capital Markets Day today on May, 29

Meet the future of antibody-based immuno-oncology drugs

Lund, Sweden, May 29, 2018 - Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, today hosts a capital markets day in Stockholm. 

The capital markets day takes place at GT 30, Grev Turegatan 30 in Stockholm. The program will start at 2:00 pm CEST, with registration from 1:00 pm CEST.  

The agenda for the day: 

  1. WELCOME | Charlotte Stjerngren, Moderator 
  2. INTRODUCTION | Per Norlén, CEO 
  3. THE ALLIGATOR STORY | Carl Borrebaeck, Co-founder 
  4. NAVIGATING COMPLEXITY | Peter Ellmark, VP Discovery 
  5. ADC-1013 and ATOR-1015 | Charlotte Russell, CMO 

Break 3:30 pm

  1. ATOR-1017 and ALG.APV-527 | Christina Furebring, SVP Research 
  2. MARKET OVERVIEW | Anu Balendran, VP Business Development 
  3. FINANCE | Per-Olof Schrewelius, CFO 
  4. CONCLUSION | Per Norlén, CEO 
  5. Q&A | Charlotte Stjerngren, Moderator 

Moderator for the day will be business journalist Charlotte Stjerngren. 

The event will be conducted in English and there will be a simultaneous live conference call for those unable to attend in person. The event will be available on Alligator’s website www.alligatorbioscience.com and a recording will be made available after the event.  

For further information, please contact:
Cecilia Hofvander, Director Investor Relations & Communications 
Phone: +46 46 286 44 95 
E-mail: cecilia.hofvander@alligatorbioscience.com 

The information was submitted for publication, through the agency of the contact person set out above, at 07:30 am CEST on May 29, 2018. 

About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes four lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527). ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 50 employees. For more information, please visit www.alligatorbioscience.com. 

The agenda can also be found in the attached pdf. 

About Us

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527) and novel research candidates. ADC-1013 (JNJ-64457107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 45 employees.

Subscribe

Documents & Links